[go: up one dir, main page]

AR120057A1 - Composiciones neoantigénicas y usos de estas - Google Patents

Composiciones neoantigénicas y usos de estas

Info

Publication number
AR120057A1
AR120057A1 ARP200101658A ARP200101658A AR120057A1 AR 120057 A1 AR120057 A1 AR 120057A1 AR P200101658 A ARP200101658 A AR P200101658A AR P200101658 A ARP200101658 A AR P200101658A AR 120057 A1 AR120057 A1 AR 120057A1
Authority
AR
Argentina
Prior art keywords
neoantigenic
compositions
immunotherapeutic
polypeptides
immunotherapeutic polypeptides
Prior art date
Application number
ARP200101658A
Other languages
English (en)
Inventor
Vikram Juneja
Zhengxin Dong
Robyn Jessica Eisert
Mahboubeh Kheirabadi
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of AR120057A1 publication Critical patent/AR120057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Lo divulgado en el presente documento se refiere a polipéptidos inmunoterapéuticos que comprenden neopéptidos, células presentadoras de antígeno que comprenden los polipéptidos inmunoterapéuticos y una composición farmacéutica que comprende los polipéptidos inmunoterapéuticos. En el presente documento, también se divulga la utilización de los polipéptidos inmunoterapéuticos para el tratamiento de una enfermedad o afección.
ARP200101658A 2019-06-12 2020-06-11 Composiciones neoantigénicas y usos de estas AR120057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860493P 2019-06-12 2019-06-12

Publications (1)

Publication Number Publication Date
AR120057A1 true AR120057A1 (es) 2022-02-02

Family

ID=73782265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101658A AR120057A1 (es) 2019-06-12 2020-06-11 Composiciones neoantigénicas y usos de estas

Country Status (10)

Country Link
US (1) US20230000960A1 (es)
EP (1) EP3982980A4 (es)
JP (2) JP2022536695A (es)
KR (1) KR20220062488A (es)
CN (1) CN114269357A (es)
AR (1) AR120057A1 (es)
BR (1) BR112021025050A2 (es)
CA (1) CA3141084A1 (es)
TW (1) TW202126327A (es)
WO (1) WO2020252039A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
EP4196153A4 (en) * 2020-08-13 2024-09-11 BioNTech US Inc. Ras neoantigens and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
JP2025525603A (ja) * 2022-07-20 2025-08-05 ビオンテック ユーエス インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP4640828A1 (en) * 2022-12-23 2025-10-29 Hanmi Pharm. Co., Ltd. Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the same, and use thereof
WO2025213185A1 (en) * 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
JP3782100B2 (ja) 1992-08-07 2006-06-07 エピミューン，インコーポレイティド Ｈｌａ結合性ペプチド及びその用途
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
KR20170002563A (ko) * 2014-05-06 2017-01-06 타르고바스 에이에스에이 돌연변이 ras 펩타이드를 포함하는 펩타이드 백신 및 화학 요법제
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
PE20181923A1 (es) * 2016-03-31 2018-12-11 Neon Therapeutics Inc Neoantigenos y metodos de su uso
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
JP7346291B2 (ja) * 2016-09-21 2023-09-19 アマル セラピューティクス エスエー 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
AU2018206358B2 (en) * 2017-01-04 2021-05-27 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
KR20200003390A (ko) * 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터

Also Published As

Publication number Publication date
EP3982980A1 (en) 2022-04-20
CN114269357A (zh) 2022-04-01
KR20220062488A (ko) 2022-05-17
JP2025085674A (ja) 2025-06-05
CA3141084A1 (en) 2020-12-17
JP2022536695A (ja) 2022-08-18
BR112021025050A2 (pt) 2022-05-03
WO2020252039A1 (en) 2020-12-17
TW202126327A (zh) 2021-07-16
US20230000960A1 (en) 2023-01-05
EP3982980A4 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
MX2023008895A (es) Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
UY37098A (es) Moduladores de ror-gamma
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2021004566A (es) Compuestos terapeuticos.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.